Chemiluminescence Imaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The chemiluminescence imaging market size is projected to expand from USD 4.24 billion in 2025 and USD 4.49 billion in 2026 to USD 5.98 billion by 2031, registering a CAGR of 5.89% between 2026 to 2031. This report is segmented by Product Type (Imaging Systems, Consumables/Reagents, Accessories/Software), Application (Western Blotting, Gel Documentation, Dot Blot, Immunoassay Imaging, DNA/RNA Hybridization, Luciferase Assays, Others), End User (Pharma/Biotech, Academic, Hospitals/Diagnostic Labs, Cros, Others), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Value (USD).

Global Chemiluminescence Imaging Market Trends and Insights

Expansion of Quantitative Camera-Based Western Blotting

The shift from X-ray film to scientific-grade digital camera detection remains a key driver of the chemiluminescence imaging market. Smaller academic laboratories and facilities in emerging economies have not completed this transition. Scientific CMOS sensors provide more than 75% peak quantum efficiency and 65,536 gray levels, supporting consistent quantitative protein analysis. Digital capture also retains timestamps, audit trails, and laboratory information management system data.

These capabilities support pharmaceutical quality control, where laboratories must maintain data integrity. Higher compliance requirements drive demand for premium instruments in regulated settings. Digital workflows enable consistent exposure comparison, electronic record retention, and reduced manual documentation. The market benefits as laboratories replace legacy processes with validated digital workflows that provide sensitive detection and traceable records.

Continued Use of High-Sensitivity ECL Workflows in Protein Research

ECL-based western blotting remains widely used to detect low-abundance proteins in research workflows. The method supports sensitive detection through HRP-catalyzed luminol oxidation under optimized substrate conditions. Biologics programs require repeated characterization of therapeutic antibodies and related proteins, supporting the use of validated detection methods in development and quality-control activities. The chemiluminescence imaging market remains linked to recurring testing demand. Laboratories face substantial revalidation requirements when changing established detection methods, which preserves the role of ECL workflows. Recurring substrate use also supports consumables revenue after instrument installation and limits the transition to alternative detection platforms.

Substitution by Multiplex Fluorescence and Automated Capillary Western Platforms

Near-infrared fluorescence systems offer a 4-5 order-of-magnitude dynamic range, compared with the 2-3 order range commonly associated with chemiluminescence. They detect 2-4 protein targets on a membrane without stripping and reprobing, providing laboratories with an alternative for multiplexing-focused experiments. Automated capillary western systems eliminate membrane transfer and blotting steps and complete assays in under 90 minutes, supporting high-throughput pharmaceutical screening. These alternatives constrain demand for conventional systems at the premium end of the chemiluminescence imaging market. Pressure is strongest for systems priced above USD 40,000, where laboratories have capital budgets for broader functionality. Mid-tier academic and government laboratories often have more limited budgets, making ECL-based chemiluminescence a more accessible option.

Other drivers and restraints analyzed in the detailed report include:

• Demand for Multipurpose Gel, Blot, and Luminescence Imaging Platforms
• Cloud-Connected and Automated Image Analysis Adoption
• Reproducibility and Dynamic-Range Limitations in Chemiluminescent Quantification

Segment Analysis

Chemiluminescence imaging systems held 68.40% of revenue in 2025, reflecting the capital value of instruments installed in laboratories. Service contracts, validated standard operating procedures, and operator training extend the commercial life of these systems. Consumables and reagents are forecast to grow at a CAGR of 7.90% from 2026 to 2031, as active platforms require compatible substrates and reagents throughout their operating life. This creates recurring revenue beyond the initial equipment purchase.

The installed base strengthens long-term relationships between instrument providers and laboratories. Reagent selection is often linked to validated protocols and system performance requirements, while connected platforms increase demand for accessories and software. Electronic audit trails, user access controls, and electronic signatures support regulated procurement requirements. The revenue mix can shift toward consumables, software licenses, and compliance-focused upgrades after system installation.

Complete Report Scope:

• By Product Type
  • Chemiluminescence Imaging Systems
  • Consumables and Reagents
  • Accessories and Softwares
• By Application
  • Western Blotting
  • Gel Documentation
  • Dot Blot and Slot Blot Analysis
  • Chemiluminescence Immunoassay Imaging
  • DNA and RNA Hybridization
  • Reporter Gene and Luciferase Assays
  • Others
• By End User
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Hospitals and Diagnostic Laboratories
  • Contract Research and Development Organizations
  • Forensic Laboratories
  • Food, Agriculture and Environmental Testing Laboratories
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.44% of the chemiluminescence imaging market share in 2025, supported by biopharmaceutical investments, academic research, and clinical laboratory applications. The United States accounted for a significant share of regional demand, while FDA 21 CFR Part 11 requirements increased demand for systems with electronic records and audit trails. In May 2026, Siemens Healthineers stated that its Atellica IM Testosterone II immunoassay achieved CDC Hormone Standardization Program certification for total testosterone. Canada contributed through academic and government-funded research, while Mexico expanded with increasing pharmaceutical manufacturing investments.

Europe was the second-largest regional contributor to the chemiluminescence imaging market, led by established pharmaceutical and biomedical research systems in Germany, the United Kingdom, and France. The EU In Vitro Diagnostic Regulation affected deployment timelines for new immunoassay platforms in hospitals. In August 2025, Revvity’s Euroimmun division launched the IDS i20, a CE-marked and FDA-listed platform that runs 20 analytes across six diagnostic specialties at 140 tests per hour. Brazil led demand in South America, while demand in the Middle East and Africa was concentrated in GCC hospital networks. Import dependence above 70% in developing regions made supply reliability and currency-adjusted pricing important procurement considerations.

Asia-Pacific is forecast to grow at a CAGR of 11.88% from 2026 to 2031, the highest rate in the chemiluminescence imaging market. Government-directed proteomics spending, biopharmaceutical manufacturing growth, and clinical diagnostics investments support demand. China’s precision medicine and biotechnology programs strengthen research infrastructure, while Tanon Science & Technology competes in mid-tier imaging systems. India is expanding laboratory equipment procurement through Department of Biotechnology and Department of Science & Technology funding programs, while Japan, South Korea, Australia, Singapore, and Malaysia contribute through research, diagnostics, and biopharmaceutical manufacturing investments.

List of Companies Covered in this Report:

• Analytik Jena
• ATTO
• Azure Biosystems
• Berthold Technologies
• Bio-Rad Laboratories
• Bio-Techne
• Cleaver Scientific
• Danaher
• DiaSorin
• LI-COR, Inc.
• Merck
• Pop-Bio Ltd
• Revvity, Inc.
• Siemens Healthineers
• Syngene International
• Tanon Science & Technology Co., Ltd.
• Tecan Group
• Thermo Fisher Scientific
• UVITEC Limited
• Vilber GmbH

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support